AbCellera reported Q3 results centered on positive Phase 2 data for ABCL635, with a 4-week placebo-adjusted reduction of 5.3 moderate-to-severe hot flashes per day. The stock was roughly flat after earnings, down 0.3%, indicating a neutral market reaction.
AbCellera's stock rose 7.2% after announcing sizable upfront payments from its new T cell engager (TCE) collaborations with Vertex and Jazz Pharmaceuticals, which added over $110 million in near-term cash and significant potential downstream revenue.
Shares declined 5.7% as investors reacted negatively to cautious outlook signals embedded in the update, notably the absence of new guidance and limited visibility on upcoming catalysts despite the Phase I data release.